Proton Therapy in Laryngeal Carcinoma: Overview

Introduction

Laryngeal carcinoma arises within the larynx, an organ that plays an essential role in phonation, deglutition, and airway protection. Beyond its oncologic implications, disease in this area substantially affects quality of life. Conventional external beam radiotherapy (EBRT) remains a standard modality, yet this standard photon-based (X-ray or gamma-radiation) techniques inevitably deliver radiation to adjacent normal tissues, increasing the risk of both acute and late toxicities.

Proton beam therapy (PBT), by contrast, offers a dosimetric advantage due to its physical properties — specifically the Bragg Peak phenomenon — enabling greater conformity of dose distribution and reduced exit dose. This precision is of particular relevance in head and neck malignancies, where organ preservation and functional outcomes (voice and swallowing) are critical.

Principles of Proton Beam Therapy (PBT)

PBT employs accelerated protons —positively charged subatomic particles— that deposit the majority of their energy at a depth corresponding to the tumor target, with a sharp fall-off in dose beyond the Bragg Peak. This contrasts with conventional radiation therapy, which deposits dose along their entire path.

In laryngeal cancer, this allows for:

• Maximal tumoricidal dose delivery within the primary site.
• Reduced irradiation of critical adjacent structures, including the vocal cords, pharyngeal muscles, esophagus, salivary glands, and carotid arteries.

Treatment Workflow

• Treatment Planning
  High-precision imaging techniques (CT, MRI, and sometimes PET) and 3D planning allow for detailed determination of tumor boundaries and critical organs, and the creation of a precise radiation treatment map.

• Patient Positioning
  The patient is placed in the proton therapy unit, where their position is secured using a custom-fitted mask and other immobilization methods. It is crucial that the patient remain still during the treatment session, so general anesthesia may be required if the patient has difficulty remaining still.

• Beam Generation
  Protons are accelerated in a cyclotron, resulting in an ionizing energy beam at the exit.

• Beam Delivery
  Various intensity-modulated techniques (IMPT) are used to deliver the required radiation dose precisely to the tumor. Upon exiting the gantry, the radiation energy is directed precisely to the tumor at a pre-calculated dose.

This workflow is especially advantageous in head and neck oncology, where sub-millimeter precision is often necessary.

Potential Benefits in the treatment of Laryngeal Cancer

• Phonatory function preservation – reduced radiation dose to the vocal cords may result in improved long-term voice preservation.
• Sparing of critical OAR organs  – decreased exposure of the esophagus, salivary glands, and carotid vessels lowers risks of xerostomia, dysphagia, and radiation-induced vasculopathy.
• Reduced toxicity profile – studies confirm a lower incidence of acute dermatitis, mucositis, and late-onset cervical fibrosis compared with traditional radiation therapy.

Clinical Indications

Proton beam therapy (PBT) may be considered in:

• Early-stage (T1–T2) laryngeal carcinoma, where local control is comparable to EBRT but toxicity may be reduced.
• Re-irradiation settings, following prior conventional radiation therapy where normal tissue tolerance is compromised.
• Patients who are not surgical candidates due to comorbidities or contraindications to anesthesia.
• Tumors adjacent to critical anatomy, requiring stringent dose limitations to preserve function and reduce late effects.

Clinical decision-making should integrate tumor staging, anatomic extent, prior treatment history, and patient’s comorbidity profile.

Evidence from Clinical Studies

Emerging literature indicates:

• Local control outcomes with proton beam therapy (PBT) are equivalent to those with conventional radiation therapy (EBRT) for early-stage laryngeal carcinoma.
• Functional preservation of voice and swallowing may be superior in some patients treated with PBT.
• Reduced late toxicities, including xerostomia, dysphagia, and cervical fibrosis, have been observed in comparative dosimetric and clinical studies.

However, randomized controlled trials are limited, and much of the evidence is derived from retrospective series and dosimetric modeling studies.

Limitations and Considerations

• Acute and late toxicity – despite that risks of edema, fibrosis, and impaired laryngeal function are reduced, they may appear in some patients treated with PBT.
• Resource constraints – proton facilities are limited geographically and financially are more resource-intensive than conventional radiotherapy centers.

Treatment logistics – daily fractionation schedules over several weeks are still required.

Recent Scientific Publications

A major study  — the Phase III Randomized Trial of Intensity-Modulated Proton Therapy (IMPT) versus Intensity-Modulated Radiation Therapy (IMRT) for Oropharyngeal Cancer — was recently completed by researchers from leading cancer centers in the United States.

This trial compared proton therapy with the most advanced form of standard radiation (IMRT) in patients with oropharyngeal cancers (the oropharynx is the part of the throat behind the mouth).

The key findings were:

• Cancer control was the same for both treatments. Proton therapy was just as effective as IMRT in preventing recurrence.
• Side effects were lower with proton therapy. Patients treated with protons were less likely to require a feeding tube and were better able to keep up their nutrition during treatment.
• Weight loss was less common in the proton therapy group compared to the IMRT group.

Although this trial focused on oropharyngeal rather than laryngeal cancer, the results are important. They demonstrate that proton therapy can control cancer just as effectively as conventional radiation while reducing certain side effects. For laryngeal cancer, where maintaining voice and swallowing function is especially critical, these benefits may be highly relevant.

Conclusion

Proton beam therapy represents a technically advanced radiotherapeutic option for the treatment of laryngeal carcinoma, offering enhanced dose distribution and potential reduction of toxicity compared with traditional radiation therapy. Clinical data shows  comparable oncologic control with possible improvements in functional outcomes, particularly in voice and swallowing preservation.

Optimal patient selection remains essential, and further prospective trials are needed to validate long-term efficacy and toxicity profiles. Multidisciplinary evaluation is recommended to determine the appropriateness of PBT on a case-by-case basis.